<

Of Course 23andMe's Plan Has Been to Sell Your Genetic Data All Along

Today, 23andMe announced what Forbes reports is only the first of ten deals with big biotech companies: Genentech will pay up to $60 million for access to 23andMe's data to study Parkinson's. You think 23andMe was about selling fun DNA spit tests for $99 a pop? Nope, it's been about selling your data all along. » 1/06/15 3:35pm 1/06/15 3:35pm